New Partnership Connects Leadership Excellence to Improved Post-Acute Care 
MentalHealth.com Acquires Online Mental Health Platform and Community
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2024 / Leading patient-first health technology company MentalHealth.com is pleased to announce...
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage...
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to...
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in...
GeneDx Announces Preliminary 2023 Financial Results
Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with...
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s...
Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter
ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular...
Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil
Advanced technology enables the land-based production of omega-3 (EPA+DHA) in Camelina potentially representing a novel solution to the market need...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
Achieving scale with pro forma full year 2023 revenue of approximately $192 millionSOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE...
Evaxion Announces Plan to Implement ADS Ratio Change
COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone...
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
Announces senior leadership appointments to further support client programs and growing sales pipelineDURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) --...
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58%Full year revenue expected...
CorMedix Inc. Announces Commercial and Operational Updates
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust...
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023
Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE...
SS Innovations Achieves Significant Milestones in 2023
Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more...